Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells
Diabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Bioengineered |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21655979.2021.1957748 |
id |
doaj-e1c611289b7046fe90220f62cddee4b9 |
---|---|
record_format |
Article |
spelling |
doaj-e1c611289b7046fe90220f62cddee4b92021-08-24T15:34:22ZengTaylor & Francis GroupBioengineered2165-59792165-59872021-01-011214805481510.1080/21655979.2021.19577481957748Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cellsLing Li0Kelei Qian1Yuli Sun2Yong Zhao3Yun Zhou4Ying Xue5Xinyu Hong6Tongji Hospital, School of Medicine, Tongji UniversityShanghai Municipal Center for Disease Control and PreventionShanghai Municipal Center for Disease Control and PreventionTongji Hospital, School of Medicine, Tongji UniversityTongji Hospital, School of Medicine, Tongji UniversityTongji Hospital, School of Medicine, Tongji UniversityShanghai Municipal Center for Disease Control and PreventionDiabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type II diabetes, it has been recently reported to possess a significant anti-inflammatory property. This study aims to explore the potential therapeutic effects of Omarigliptin on DN. We established an in vitro injury model in human renal glomerular endothelial cells (HrGECs) using high glucose (HG). The severe cytotoxicity and increased oxidative stress in HrGECs induced by HG were pronouncedly reversed by the introduction of Omarigliptin. Furthermore, the activated NLRP3 inflammasome and the excessive production of interleukin 18 (IL-18) and interleukin 1β (IL-1β) in HrGECs induced by incubation with HG were pronouncedly reversed by the introduction of Omarigliptin, accompanied by the activation of the AMPK/mTOR signaling pathway. After the co-administration of the adenosine monophosphate-activated protein kinase α (AMPKα) inhibitor, compound C, the protective effects of Omarigliptin against HG-induced NLRP3 inflammasome activation and production of pro-inflammatory factors were dramatically abolished. Taken together, our data revealed that Omarigliptin ameliorated HG-induced inflammation in renal glomerular endothelial cells through suppressing NLRP3 inflammasome activation mediated by AMPKα.http://dx.doi.org/10.1080/21655979.2021.1957748omarigliptinampknlrp3 inflammasomediabetic nephropathy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ling Li Kelei Qian Yuli Sun Yong Zhao Yun Zhou Ying Xue Xinyu Hong |
spellingShingle |
Ling Li Kelei Qian Yuli Sun Yong Zhao Yun Zhou Ying Xue Xinyu Hong Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells Bioengineered omarigliptin ampk nlrp3 inflammasome diabetic nephropathy |
author_facet |
Ling Li Kelei Qian Yuli Sun Yong Zhao Yun Zhou Ying Xue Xinyu Hong |
author_sort |
Ling Li |
title |
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells |
title_short |
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells |
title_full |
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells |
title_fullStr |
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells |
title_full_unstemmed |
Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells |
title_sort |
omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (nlrp3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (ampkα) in renal glomerular endothelial cells |
publisher |
Taylor & Francis Group |
series |
Bioengineered |
issn |
2165-5979 2165-5987 |
publishDate |
2021-01-01 |
description |
Diabetic nephropathy (DN) is a complication of diabetes that induces the development of end-stage renal disease (ESRD). The pathogenesis of DN is reported to be closely related to the activation of the NOD-like receptor 3 (NLRP3) inflammasome in renal glomerular endothelial cells. Omarigliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type II diabetes, it has been recently reported to possess a significant anti-inflammatory property. This study aims to explore the potential therapeutic effects of Omarigliptin on DN. We established an in vitro injury model in human renal glomerular endothelial cells (HrGECs) using high glucose (HG). The severe cytotoxicity and increased oxidative stress in HrGECs induced by HG were pronouncedly reversed by the introduction of Omarigliptin. Furthermore, the activated NLRP3 inflammasome and the excessive production of interleukin 18 (IL-18) and interleukin 1β (IL-1β) in HrGECs induced by incubation with HG were pronouncedly reversed by the introduction of Omarigliptin, accompanied by the activation of the AMPK/mTOR signaling pathway. After the co-administration of the adenosine monophosphate-activated protein kinase α (AMPKα) inhibitor, compound C, the protective effects of Omarigliptin against HG-induced NLRP3 inflammasome activation and production of pro-inflammatory factors were dramatically abolished. Taken together, our data revealed that Omarigliptin ameliorated HG-induced inflammation in renal glomerular endothelial cells through suppressing NLRP3 inflammasome activation mediated by AMPKα. |
topic |
omarigliptin ampk nlrp3 inflammasome diabetic nephropathy |
url |
http://dx.doi.org/10.1080/21655979.2021.1957748 |
work_keys_str_mv |
AT lingli omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells AT keleiqian omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells AT yulisun omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells AT yongzhao omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells AT yunzhou omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells AT yingxue omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells AT xinyuhong omarigliptinamelioratedhighglucoseinducednucleotideoligomerizationdomainlikereceptorprotein3nlrp3inflammasomeactivationthroughactivatingadenosinemonophosphateactivatedproteinkinaseaampkainrenalglomerularendothelialcells |
_version_ |
1721197304868765696 |